Johansson Klara, Stenman Adam, Paulsson Johan O, Wang Na, Ihre-Lundgren Catharina, Zedenius Jan, Juhlin C Christofer
Department of Oncology-Pathology, Karolinska Institutet, BioClinicum J6:20, Visionsgatan 4, SE-17164, Solna, Sweden.
Department of Breast, Endocrine Tumors and Sarcoma, Karolinska University Hospital, Stockholm, Sweden.
Thyroid Res. 2021 Aug 14;14(1):19. doi: 10.1186/s13044-021-00110-4.
Thyroid cancer dedifferentiation is an unusual observation among young patients and is poorly understood, although a recent correlation to DICER1 gene mutations has been proposed.
A 28-year old patient presented with a sub-centimeter cytology-verified primary papillary thyroid carcinoma (PTC) and a synchronous lateral lymph node metastasis. Following surgery, histopathology confirmed a 9 mm oxyphilic PTC and a synchronous metastasis of poorly differentiated thyroid carcinoma (PDTC). Extensive molecular examinations of both lesions revealed wildtype DICER1 sequences, but identified a somatic ETV6-NTRK3 gene fusion and a MET germline variant (c.1076G > A, p.Arg359Gln). MET is an established oncogene known to be overexpressed in thyroid cancer, and this specific alteration was not reported as a single nucleotide polymorphism (SNP), suggestive of a mutation. Both the primary PTC and the metastatic PDTC displayed strong MET immunoreactivity. A validation cohort of 50 PTCs from young patients were analyzed using quantitative real-time PCR, revealing significantly higher MET gene expression in tumors than normal thyroid controls, a finding which was particularly pronounced in BRAF V600E mutated cases. No additional tumors apart from the index case harbored the p.Arg359Gln MET mutation. Transfecting PTC cell lines MDA-T32 and MDA-T41 with a p.Arg359Gln MET plasmid construct revealed no obvious effects on cellular migratory or invasive properties, whereas overexpression of wildtype MET stimulated invasion.
The question of whether the observed MET mutation in any way influenced the dedifferentiation of a primary PTC into a PDTC metastasis remains to be established. Moreover, our data corroborate earlier studies, indicating that MET is aberrantly expressed in PTC and may influence the invasive behavior of these tumors.
甲状腺癌去分化在年轻患者中并不常见,人们对此了解甚少,尽管最近有人提出它与DICER1基因突变有关。
一名28岁患者,经细胞学检查证实为亚厘米级原发性乳头状甲状腺癌(PTC),并伴有同步侧方淋巴结转移。手术后,组织病理学证实为9毫米嗜酸细胞性PTC和低分化甲状腺癌(PDTC)的同步转移。对这两个病灶进行的广泛分子检测显示DICER1序列为野生型,但发现了一种体细胞ETV6-NTRK3基因融合和一种MET种系变异(c.1076G>A,p.Arg359Gln)。MET是一种已知在甲状腺癌中过度表达的癌基因,这种特定改变未被报告为单核苷酸多态性(SNP),提示为一种突变。原发性PTC和转移性PDTC均显示出强烈的MET免疫反应性。使用定量实时PCR对50例年轻患者的PTC验证队列进行分析,结果显示肿瘤中MET基因表达明显高于正常甲状腺对照,这一发现在BRAF V600E突变病例中尤为明显。除索引病例外,没有其他肿瘤携带p.Arg359Gln MET突变。用p.Arg359Gln MET质粒构建体转染PTC细胞系MDA-T32和MDA-T41,未发现对细胞迁移或侵袭特性有明显影响,而野生型MET的过表达则刺激了侵袭。
观察到的MET突变是否以任何方式影响原发性PTC向PDTC转移的去分化问题仍有待确定。此外,我们的数据证实了早期研究,表明MET在PTC中异常表达,并可能影响这些肿瘤的侵袭行为。